These consensus guidelines are significant not only for their key updates to clinical practice but for their representation of a more [...]
The CMSC Board, staff, and members would like to congratulate Dr. Robert Lisak for his selection as a recipient of the 2021 Distinguished [...]
Bristol Myers Squibb is conducting a Phase 3b Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing [...]
– 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity [...]
Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy [...]
Head-to-head pivotal clinical trial results showed PONVORY™ treatment led to nearly a third fewer annual relapses than [...]
A diverse panel including an expert neurologist, a psychologist, a patient, and a care partner discuss the patient's journey with [...]
Please be advised of the recent approval by the FDA for intramuscular Plegridy (Peginterferon beta-1a) and an update to other sections [...]
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a [...]
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]